Xencor (NASDAQ:XNCR) Upgraded at Barclays

Barclays upgraded shares of Xencor (NASDAQ:XNCR) to a strong sell rating in a report issued on Tuesday morning,Zacks.com reports.

Several other brokerages have also weighed in on XNCR. Wedbush reiterated an “outperform” rating and issued a $26.00 price objective on shares of Xencor in a research report on Tuesday, September 2nd. Wells Fargo & Company reduced their price objective on Xencor from $33.00 to $27.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Bank of America cut Xencor from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $23.00 to $12.00 in a research note on Wednesday, September 3rd. Finally, Royal Bank Of Canada reduced their price objective on Xencor from $32.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday, August 21st. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Xencor currently has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Xencor Price Performance

Xencor stock opened at $10.03 on Tuesday. The business has a fifty day moving average price of $8.35 and a 200-day moving average price of $9.24. Xencor has a 1-year low of $6.92 and a 1-year high of $27.24. The stock has a market capitalization of $715.37 million, a price-to-earnings ratio of -4.18 and a beta of 0.82.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.37. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The business had revenue of $43.61 million during the quarter, compared to analysts’ expectations of $22.59 million. During the same quarter in the prior year, the firm earned ($1.07) earnings per share. The business’s revenue was up 82.4% compared to the same quarter last year. On average, equities research analysts anticipate that Xencor will post -3.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of XNCR. GF Fund Management CO. LTD. acquired a new stake in shares of Xencor during the 4th quarter worth $34,000. State of Wyoming acquired a new stake in shares of Xencor during the 1st quarter worth $34,000. CWM LLC increased its holdings in shares of Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 2,231 shares during the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Xencor during the 4th quarter worth $101,000. Finally, AlphaQuest LLC acquired a new stake in shares of Xencor during the 1st quarter worth $56,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.